One RCT showed that treatment with ticagrelor reduced the inflammatory burden through a reduction in levels of IL-1α, IL-1β, and TNFα in non-dialysis patients with CKD stage 4–5 [50]. This evidence concerns the gene IL1A and chronic kidney disease.